Background: Critical hand ischaemia (CHI) of the upper extremity is rarely encountered. Axillary, brachial and below-the-elbow (BTE) disease is often asymptomatic due to highly developed collaterals, but in diffuse-multiple and thrombotic disease CHI can develop. The aim of this prospective study was to assess the feasibility, safety and outcomes of percutaneous transluminal angioplasty (PTA) in the treatment of CHI. Methods: Twenty-one patients (age 72 Ϯ 13 years; six females) were treated with angioplasty in 2011 (16 pain at rest; 2 non-healing ulcer; 3 gangrene) due to axillarybrachial and pure BTE artery disease. We examined the procedural and clinical success and the rate of major adverse events (MAE) and vascular complications. Results: One patient had Takayasu arteritis and 3 patients had symptomatic radial artery occlusion after transradial PCI in the investigated population. Six patients (nϭ6, 29%) had subacute occlusion and 11 patients had chronic disease (nϭ15, 71%). Multilevel (nϭ8, 38%), unilevel dilatations (13, 62%) and in 3 cases parallel dilatations were performed (nϭ3, 14%). Angioplasty was performed in the axillary (nϭ6), brachial (nϭ12), radial (nϭ5), ulnar (nϭ8), interosseus (nϭ1) and in palmar arch (nϭ2). Technical success rate was 95% (20/21). Successful mechanical (Rotarex, nϭ1, 17%) and aspiration thrombectomy (nϭ5, 83%) was performed in subacute cases, before angioplasty (nϭ6, 100%) and stenting (nϭ3, 50%). In chronic cases angioplasty was performed in all cases (15, 100%) and additional stenting was necessary in 6 cases (40%). PTA was unsuccessful in one patient (1/21, 5%). The hand-healing rate in the patients with gangrene and non-healing ulcer was 100% (5/5), and the relief of the pain was observed in 20 patients (20/21, 95%). Two patients (nϭ2, 9.5%) underwent secondary procedures due to symptomatic restenosis. The MAE rate was 0% during follow-up. One vascular complication (5%) occurred in the investigated population (radial artery perforation successfully treated with compression bandage). Conclusions: Angioplasty of the hand vessels for CHI is a feasible and safe procedure with acceptable rates of technical success and hand healing.
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Background: The Chocolate FIM Study will confirm device safety and assess the occurrence of vascular and procedural complications after treatment with the novel Chocolate PTA Balloon Catheter. Methods: Angioplasty for peripheral vascular disease is often associated with acute complications following inflation and deflation of a standard balloon. Such complications are commonly considered to be related to vessel trauma and often require bailout stenting. The Chocolate PTA Balloon Catheter (developed by Quattro Vascular, Singapore/ distributed by TriReme Medical, CA) is a novel balloon catheter with a mounted constraining structure to allow for uniform inflation and rapid deflation. The attributes of the constrained balloon are designed for modulated dilatation and creation of small balloon segments ("pillows"), intended to minimize vessel damage. The first in man use of this novel device is described here. Acute assessments include: technical success (Ͻ50% residual stenosis without flow-limiting dissection), rate of bailout stenting, and occurrence/severity of dissection and the occurrence of in-hospital major adverse events (MAE-defined as TLR, death, or major amputation). All treatment angiograms are independently reviewed by a core lab to confirm vascular outcomes after treatment with the Chocolate Balloon. Clinical and Duplex Ultrasound follow-up at 1, 6, and 12 months is on-going. Results: The Chocolate Balloon has been used in the first 22 patients (58% CLI) to treat BTK target lesions (average length 11cm). The Chocolate device was used successfully in a diverse range of BTK vessels (AT (48%), PER (14%), Trunk only (14%), Trunk to PER (14%), Trunk to PT (5%), PT (3%)). Acute results include successful delivery and deployment in all cases. Technical Success is 100%. Bail-out stenting is 0%. No flow-limiting dissection has been reported for any Chocolate case. No in-hospital or 30 day MAEs has been reported. 6 Month MAE and Patency data will be included in presentation. Conclusions: These initial cases verify that the Chocolate Balloon is safe for use. These early data also present compelling evidence to suggest that the design of the Chocolate Balloon is effective in reducing proced. Methods: Primary endpoints were survival free from amputation and sustained clinical improvement. Secondary endpoints were major adverse events (MAE), the binary restenosis rate, freedom from TLR, and a special quality-adjusted life year (QALY) endpoint (Q-TWiST) that incorporated both length and quality of life to evaluate treatments. Results: At 5 years, clinical improvement was sustained in 82.8% of the SIA group versus 68.2% of the BG patients (p50.106). Five-year all-cause survival was similar for SIA (78.6%) and BG (80.1%; pϭ0.734), as was amputation-free survival (SIA 72.9% versus BG 71.2%; pϭ0.976) . Hyperfibrinogenemia (pϭ0.009) and C-reactive protein (pϭ0.019) had negative effects on survival without amputation. Five-year freedom from binary restenosis rates were 72.8% for SIA versus 65.3% for BG (pϭ0.700). While the 5-year freedom from TLR rates (SIA 85.9% versus BS 72.1%, pϭ0.262) were not statistically significant, the risk of MAE (pϽ0.002) and length of hospital stay (pϽ0.0001) were significantly reduced. Q-TWiST significantly improved (pϽ0.001) and cost-per-QALY was reduced with SIA. The 5-year risk of re-intervention (pϾ0.05) and mean number of procedures (pϭ0.078) were similar. Conclusions: Five-year freedom from MAE was enhanced by 20% in the SIA group, with substantial cost reduction and better Q-TWiST. SIA is a minimally invasive technique that expands amputation-free and symptom-free survival. SIA is a paradigm shift in the management of CLI.
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